Broadwater Capital’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$408K Hold
6,545
– – 0.29% 59
2026
Q2
$377K Sell
6,545
-1,185
-15% -$68K 0.27% 58
2026
Q1
$417K Hold
7,730
– – 0.31% 56
2025
Q4
$417K Sell
7,730
-1,170
-13% -$56.3K 0.31% 56
2025
Q3
$401K Hold
8,900
– – 0.29% 58
2025
Q2
$412K Hold
8,900
– – 0.32% 60
2025
Q1
$543K Hold
8,900
– – 0.42% 50
2024
Q4
$503K Hold
8,900
– – 0.39% 50
2024
Q3
$460K Sell
8,900
-1,580
-15% -$74.1K 0.34% 56
2024
Q2
$435K Sell
10,480
-4,740
-31% -$212K 0.34% 55
2024
Q1
$825K Hold
15,220
– – 0.63% 42
2023
Q4
$781K Buy
+15,220
New +$799K 0.61% 43

Other funds holding BMY

Broadwater Capital's BMY Position: Q3 2026 in Review

Broadwater Capital held its Bristol-Myers Squibb (BMY) position steady in Q3 2026 at 6,545 shares worth $408K. The position accounts for 0.29% of the portfolio, ranked #59.

Broadwater Capital first reported a position in BMY in Q4 2023 and has held it in 12 quarters since. The position peaked at $825K in Q1 2024. 2,533 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Broadwater Capital held 6,545 shares of Bristol-Myers Squibb worth $408K as of Q3 2026.
  • Broadwater Capital left its Bristol-Myers Squibb share count unchanged in Q3 2026.
  • Bristol-Myers Squibb made up 0.29% of Broadwater Capital's portfolio in Q3 2026, its #59 holding.
  • Broadwater Capital first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 12 quarters since.
  • Broadwater Capital's Bristol-Myers Squibb position peaked at $825K in Q1 2024.
  • 2,533 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Broadwater Capital's 13F filing for Q3 2026, filed 12 Nov 2026.